Group 1 - Yara International's chairman was arrested for embezzlement and abuse of power, but the company's operations remain normal and control has not changed [2][9] - Tenglong Co., Ltd. reported that it has small-scale products indirectly applied in data center/server liquid cooling and energy storage liquid cooling, with limited revenue impact [3] - Xianda Co., Ltd. achieved a net profit of 136 million yuan in the first half of 2025, a year-on-year increase of 2561.58%, driven by rising product prices and new product launches [4][25] Group 2 - Jifeng Technology announced a collective resignation of its board members, leading to a change in control [5] - Xiling Information's controlling shareholder is under investigation, but the company's control remains unchanged [6] - Chitianhua's subsidiary plans a scheduled maintenance shutdown for 35 days, which will not affect annual production targets [7] Group 3 - Shentong Express reported a revenue of 4.287 billion yuan in July 2025, a year-on-year increase of 9.95% [8] - Tianyu Digital's board member was arrested for embezzlement, but the company maintains normal operations [9] - Shaanxi Natural Gas's controlling shareholder plans to transfer 13% of its shares, affecting the ownership structure [9] Group 4 - Kesheng Technology's actual controller is under investigation, but the company's operations remain normal [10] - Dazhu CNC reported a net profit of 263 million yuan in the first half of 2025, a year-on-year increase of 83.82% [11] - Jinli Permanent Magnet's net profit increased by 155% year-on-year, with significant sales in the new energy vehicle sector [12] Group 5 - China Shenhua's expansion project for the Wanzhou power plant has been approved with a total investment of 6.655 billion yuan [13] - Wanfu Biology reported a net profit of 189 million yuan in the first half of 2025, a year-on-year decrease of 46.82% [13] - Round Express reported a revenue increase of 12.08% in July 2025 [13] Group 6 - Soft Control Co., Ltd. reported a net profit decrease of 23.84% in the first half of 2025 [21] - Jiangte Electric's subsidiary has completed maintenance and will resume production [21] - Blue Ocean Huaten reported a net profit increase of 159.83% in the first half of 2025 [22]

Core Viewpoint - The company XinNuoWei announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - The approval pertains to the clinical trial notification for Dupilumab injection [1] - The clinical trials are expected to begin in the near future [1]

Core Viewpoint - The announcement by XinNuoWei regarding the approval of clinical trials for Dupilumab injection marks a significant step in the development of a biosimilar drug targeting IL-4Rα for the treatment of moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for Dupilumab injection [1] - Dupilumab injection is a fully human monoclonal antibody drug and is classified as a biosimilar to Dupixent [1] Industry Summary - The drug is categorized under biological products for therapeutic use, specifically as a Class 3.3 application, indicating its relevance in the biopharmaceutical sector [1] - The indication for Dupilumab injection is aimed at treating adults with moderate to severe atopic dermatitis, highlighting the growing demand for effective treatments in this therapeutic area [1]

石药集团(01093)发布公告，本集团开发的度普利尤单抗注射液(该产品)已获中国国家药品监督管理局批 准，可在中国开展临床试验。 该产品是一种靶向IL-4Rα的重组全人源单克隆抗体药物，为达必妥的生物类似药，按照治疗用生物制品 3.3类申报，适用于治疗成人中重度特应性皮炎。 该产品的研发遵循生物类似药相关研究指南。药学及非临床研究结果显示，该产品与原研参照药在质 量、安全性和有效性方面高度相似，支持开展后续临床研究。 ...

Core Viewpoint - The announcement indicates that CSPC Pharmaceutical Group (01093.HK) has received approval from the National Medical Products Administration of China to conduct clinical trials for Dupilumab Injection, a biosimilar to Dupixent, targeting moderate to severe atopic dermatitis in adults [1] Group 1: Product Development - The product is a recombinant fully human monoclonal antibody drug targeting IL-4Rα, classified as a biosimilar to Dupixent [1] - The application was submitted under the category of biological products for therapeutic use, specifically Class 3.3 [1] - The research results from pharmaceutical and non-clinical studies demonstrate high similarity in quality, safety, and efficacy compared to the reference drug, supporting the initiation of subsequent clinical studies [1]

Group 1 - The core point of the article is that CSPC Pharmaceutical Group (01093) has received approval from the National Medical Products Administration of China to conduct clinical trials for its drug Dupilumab Injection [1] - The product is a recombinant fully human monoclonal antibody targeting IL-4Rα and is a biosimilar to Dupixent, classified under Category 3.3 for therapeutic biological products [1] - The drug is intended for the treatment of moderate to severe atopic dermatitis in adults [1] Group 2 - The development of the product follows the relevant research guidelines for biosimilars [1] - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting the initiation of subsequent clinical studies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的度普利尤單抗注射液（「該產品」）已獲中華人民共和國國家藥品監督管理 局批准，可在中國開展臨床試驗。 該產品是一種靶向IL -4Rα的重組全人源單克隆抗體藥物，為達必妥®的生物類似藥，按照 治療用生物製品3.3類申報，適用於治療成人中重度特應性皮炎。 該產品的研發遵循生物類似藥相關研究指南。藥學及非臨床研究結果顯示，該產品與原研 參照藥在質量、安全性和有效性方面高度相似，支持開展後續臨床研究。 代表董事會 石藥集團有限公司 主席 蔡東晨 香港，2025年8月19日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 ...

Core Viewpoint - The company XinNuoWei has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a monoclonal antibody drug targeting IL-4Rα, which is a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has been authorized to conduct clinical trials for Dupilumab injection [1] - The drug is classified as a Class 3.3 biological product for therapeutic use [1] Industry Summary - Dupilumab injection is positioned as a biosimilar to Dupixent, indicating a competitive entry into the market for treatments of atopic dermatitis [1] - The approval for clinical trials reflects ongoing advancements in biopharmaceuticals targeting specific conditions such as atopic dermatitis [1]

新诺威8月19日公告，公司控股子公司巨石生物近日收到国家药品监督管理局核准签发的关于度普利尤 单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。度普利尤单抗注射液是一款靶向 IL-4Rα的重组全人源单克隆抗体药物，为达必妥®的生物类似药，适用于治疗成人中重度特应性皮炎。 ...

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - Dupilumab injection is a recombinant fully human monoclonal antibody drug targeting IL-4Rα, developed as a biosimilar to Dupixent [1] - The drug is classified under Category 3.3 for therapeutic biological products and is intended for the treatment of moderate to severe atopic dermatitis in adults [1] - The research and development of this product adhere to the relevant guidelines for biosimilars, with pharmaceutical and non-clinical research results indicating high similarity in quality, safety, and efficacy compared to the reference drug [1]